Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib plus sintilimab as first-line therapy for advanced non-liver metastatic colorectal cancer
ChiCTR2600119128Phase 2Not yet recruiting
- Sponsor
- Shanghai Changzheng Hospital
- Start
- Feb 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of anlotinib and sintilimab in colorectal adenocarcinoma, sponsored by Shanghai Changzheng Hospital. Primary endpoints: Objective response rate, Deepness of response and 2 more. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
anlotinibsintilimab
03
Conditions
colorectal adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2600119128.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600119128.